中国现代医药杂志
中國現代醫藥雜誌
중국현대의약잡지
MODERN MEDICINE JOURNAL OF CHINA
2015年
1期
34-36
,共3页
孔繁宇%邓家强%刘军明%廖志山%富蓉%魏峥%黄健安%邓俊明%范志勇%张琴
孔繁宇%鄧傢彊%劉軍明%廖誌山%富蓉%魏崢%黃健安%鄧俊明%範誌勇%張琴
공번우%산가강%류군명%료지산%부용%위쟁%황건안%산준명%범지용%장금
慢性心力衰竭%慢性阻塞性肺疾病%比索洛尔%美托洛尔
慢性心力衰竭%慢性阻塞性肺疾病%比索洛爾%美託洛爾
만성심력쇠갈%만성조새성폐질병%비색락이%미탁락이
Chronic heart failure%Chronic obstructive pulmonary disease%Bisoprolol%Metoprolol
目的:探讨比索洛尔和美托洛尔在慢性心力衰竭(CHF)合并慢性阻塞性肺疾病(COPD)患者的疗效差异。方法随机抽取63例患者,分别患有轻到中度CHF和中到重度COPD,在治疗前和治疗中进行肺功能试验、12导联心电图和N端脑利钠肽检查。结果31例患者达到两种药物的目标剂量,19例在治疗中出现不良反应(比索洛尔19%,美托洛尔42%,P=0.045);8例患者因不良反应而停药(比索洛尔组:2例因低血压,1例因心动过缓;美托洛尔组:2例因低血压,3例分别因哮喘、呼吸困难和水肿)。比索洛尔组比美托洛尔组患者的第1秒用力呼气量显著增加(比索洛尔组:1561±414ml vs 1698±519ml,P=0.046;美托洛尔组:1704±484ml vs 1734±548ml,P=0.441)。两种药物均降低了心率(比索洛尔组:75±14 vs 68±10,P=0.007;美托洛尔组:78±14 vs 72±12,P=0.016)。然而均未对N端脑利钠肽产生影响。结论β受体阻滞剂常引起不良反应,只有49%的患者可耐受目标剂量。研究表明,比索洛尔比美托洛尔能够较好改善肺功能状态且引起的不良反应少。
目的:探討比索洛爾和美託洛爾在慢性心力衰竭(CHF)閤併慢性阻塞性肺疾病(COPD)患者的療效差異。方法隨機抽取63例患者,分彆患有輕到中度CHF和中到重度COPD,在治療前和治療中進行肺功能試驗、12導聯心電圖和N耑腦利鈉肽檢查。結果31例患者達到兩種藥物的目標劑量,19例在治療中齣現不良反應(比索洛爾19%,美託洛爾42%,P=0.045);8例患者因不良反應而停藥(比索洛爾組:2例因低血壓,1例因心動過緩;美託洛爾組:2例因低血壓,3例分彆因哮喘、呼吸睏難和水腫)。比索洛爾組比美託洛爾組患者的第1秒用力呼氣量顯著增加(比索洛爾組:1561±414ml vs 1698±519ml,P=0.046;美託洛爾組:1704±484ml vs 1734±548ml,P=0.441)。兩種藥物均降低瞭心率(比索洛爾組:75±14 vs 68±10,P=0.007;美託洛爾組:78±14 vs 72±12,P=0.016)。然而均未對N耑腦利鈉肽產生影響。結論β受體阻滯劑常引起不良反應,隻有49%的患者可耐受目標劑量。研究錶明,比索洛爾比美託洛爾能夠較好改善肺功能狀態且引起的不良反應少。
목적:탐토비색락이화미탁락이재만성심력쇠갈(CHF)합병만성조새성폐질병(COPD)환자적료효차이。방법수궤추취63례환자,분별환유경도중도CHF화중도중도COPD,재치료전화치료중진행폐공능시험、12도련심전도화N단뇌리납태검사。결과31례환자체도량충약물적목표제량,19례재치료중출현불량반응(비색락이19%,미탁락이42%,P=0.045);8례환자인불량반응이정약(비색락이조:2례인저혈압,1례인심동과완;미탁락이조:2례인저혈압,3례분별인효천、호흡곤난화수종)。비색락이조비미탁락이조환자적제1초용력호기량현저증가(비색락이조:1561±414ml vs 1698±519ml,P=0.046;미탁락이조:1704±484ml vs 1734±548ml,P=0.441)。량충약물균강저료심솔(비색락이조:75±14 vs 68±10,P=0.007;미탁락이조:78±14 vs 72±12,P=0.016)。연이균미대N단뇌리납태산생영향。결론β수체조체제상인기불량반응,지유49%적환자가내수목표제량。연구표명,비색락이비미탁락이능구교호개선폐공능상태차인기적불량반응소。
Objective To explore effect of Bisoprolol and Metoprolol in patients with chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD). Methods Randomized 63 elderly patients with mild to moderate CHF and moderate to severe COPD. Pulmonary function testing,12-lead electrocardiogram and N-terminal pro brain natriuretic peptide were measured before and during therapy. Results 31 patients reached the target dose of two drugs, 19 cases of adverse re-actions during the treatment (Bisoprolol:19%, Metoprolol:42%,P=0.045). 8 cases of withdrawal due to adverse events (Biso-prolol: 2 cases due to hypotension,1 case due to bradycardia; Metoprolol: 2 cases due to hypotension, 3 cases respectively for wheezing, dyspnoea, and oedema). Forced expiratory volume in 1st second significantly increased in Bisoprolol (1 561±414ml vs 1 698±519ml, P=0.046; Metoprolol:1 704±484ml vs 1 734±548ml, P=0.441). Both agents reduced heart rate (Bisoprolol:75±14 vs 68±10, P=0.007; Metoprolol:78±14 vs 72±12, P=0.016) and had no effect on N-terminal pro brain natriuretic pep-tide. Conclusion Beta blockers frequently caused adverse events, and thus 49% of patients could tolerate the target dose. Bisoprolol induced demonstrable improvement in pulmonary function and caused less adverse events.